NVS 250117 100.00C (NVS250117C100000) Stock Options, News & Quotes

English
中文繁體
中文简体

Download

Mobile

moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US OptionsDetailed Quotes

NVS250117C100000

Watchlist

0.90
-0.65-41.94%

15min DelayClose Jan 10 16:00 ET

1.01High0.80Low

Intraday

5D
Daily

News

Novartis AG: Hold Rating Maintained Amid Legal Uncertainties and Limited Growth Prospects
TipRanksJan 11 10:38 ET · Ratings
Express News | Intra-Cellular Therapies Enters Settlement Agreement With Sandoz Resolving Patent Litigation Related To CAPLYTA Patent; No Terms Disclosed
BenzingaJan 10 07:07 ET
Solid Biosciences Outpaces Competitors In Duchenne Gene Therapy Development
BenzingaJan 8 14:09 ET
Bernstein Sticks to Its Buy Rating for Novartis AG (NOVN)
TipRanksJan 7 02:25 ET · Ratings
'LDH Reports First U.S. H5N1-Related Human Death' - Louisiana Department Of Health
BenzingaJan 6 15:35 ET
CVS Health's Aetna Files Lawsuit Against Drugmakers For Alleged Inflated Generic Drug Prices
BenzingaJan 6 10:40 ET

Comments

Stock_Drift

Dec 19, 2024 05:18

$BioAge Labs (BIOA.US)$ $Novartis AG (NVS.US)$

BioAge and Novartis seek drug targets for ageing-related diseases

10xStockPicks

Dec 15, 2024 18:30

A.i Predicts Big Pharma Will Soon Acquire Esperion Therapeutics for $12 to $16 A share, Current Price $2.25

$Esperion Therapeutics (ESPR.US)$ Acquiring Esperion Therapeutics could be a strategic move for a big pharmaceutical company for several compelling reasons. Here are the main factors that suggest an acquisition could be beneficial for a larger player in the pharmaceutical industry:
1. Unique Market Position in Statin Alternatives
– Addressing Statin Intolerance: There are millions of statin...

10xStockPicks

Dec 15, 2024 15:56

Buying This Takeover Target Offers 10X Upside. Esperion Therapeutics.

$Esperion Therapeutics (ESPR.US)$ $Esperion Therapeutics (ESPR.US)$ Esperion Therapeutics (ESPR) is a biotech company that focuses on developing and commercializing therapies to lower cholesterol, specifically offering the only FDA-approved statin alternatives: NEXLIZET and NEXLETOL for PRIMARY PREVENTION. These drugs are designed for individuals who are statin intolerant or cannot achieve adequate cholesterol lowering with statin...

10xStockPicks

Dec 14, 2024 21:19

This $2.25 Stock Soon To Turn A Profit Is Highly Likely To Be Acquired Above $10

This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...

Asherboy88

Dec 11, 2024 08:09

$Novartis AG (NVS.US)$ what is happening ?? keeps going down